Optimizing Early Biomarker Testing to Guide Clinical Decision-Making in Colorectal Cancer Across Latin America
Pfizer Inc.'s grant supports educational projects to improve biomarker testing and clinical decision-making in colorectal cancer care across Latin America.
Funder: Pfizer Inc.
Due Dates: September 17, 2026 (Submission Deadline)
Funding Amounts: Single-country projects: $50,000–$100,000 USD; multi-country/regional projects: up to $200,000 USD; total budget: $250,000 USD
Summary: Supports independent medical education projects that advance early biomarker testing and clinical decision-making in colorectal cancer across Latin America.
Description
This opportunity from Pfizer Inc. funds independent medical education initiatives that address gaps in knowledge, access, and implementation of biomarker testing in colorectal cancer (CRC) throughout Latin America. The program seeks to empower healthcare professionals with up-to-date evidence and best practices in precision oncology, promoting integrated, multidisciplinary care and the standardization of CRC management. Projects should focus on educational strategies that drive adoption of biomarker-driven management, improve diagnostic practices, and advance patient outcomes. Clinical research projects, or those evaluating the efficacy of therapeutic or diagnostic agents, are not eligible.
